|
|
| Wednesday May 31, 2023 |
| 16:00 | Opening & Introduction |
Dr Jean-Yves ORTHOLAND
(EDELRIS, Lyon, France) |
| Session 1 |
| 16:05 | PL01 - Accelerating Throughput of ASMS Screens by Leveraging Multiplexed LC-MS and Automated Data Processing |
Dr Gerald BARNEY
(BRISTOL MYERS SQUIBB, Princeton, United States) |
|
| 16:40 | PL02 - EDEN in Drug Discovery |
Dr Didier ROCHE
(EDELRIS, Lyon, France) |
|
| 17:00 | PL03 - Deploying Affinity Selection Mass Spectrometry (ASMS) for Rapid and Flexible Hit Confirmation of DNA-Encoded Library (DEL) Screening in Targeted Protein Modulation (TPM) |
Dr Daniel MEDINA-CLEGHORN
(NURIX THERAPEUTICS, San Francisco, United States) |
| |
|
| 17:45 | PL04 - Affinity Selection Mass Spectrometry: Hit Validation Tool and a Promising High Throughput Screening Platform for Drug Targets
|
Dr Omprakash NACHAM
(ABBVIE, North Chicago, United States) |
|
| 18:20 | Round table discussion & closing remarks |
|
|
|
| Thursday June 1, 2023 |
| 16:00 | Opening remarks Day 2 |
Dr Allen ANNIS (AILERON THERAPEUTICS, Cambridge, United States)
Prof. Wenqing SHUI (SHANGHAITECH UNIVERSITY, Shanghai, China) |
| Session 2 |
| 16:05 | PL05 - MALDI MS-based Cell Assays in Pharmaceutical R&D – a Perspective |
Prof. Carsten HOPF
(UNIVERSITY OF MANNHEIM, Mannheim, Germany) |
|
| 16:40 | PL06 - Developement of High Throughput MS within
AstraZeneca's Discovery Sciences |
Dr Jonathan WINGFIELD
(ASTRAZENECA, Macclesfield, United Kingdom) |
| |
|
| 17:25 | PL07 - Setting up an AS-MS Screening Method in Pharmaceutical Industry |
Mr Kai SINERVO
(ORION CORPORATION, Espoo, Finland) |
|
| 17:45 | PL08 - Improved ASMS Affinity Ranking Using Complete Analysis of Target Titration Data |
Dr Brett BABIN
(GENENTECH, South San Francicsco, United States) |
|
| 18:20 | Round table discussion & closing remarks |
|
|
|
|
